
	Three Months Ended March 31,
		2026		2025
Revenues		$	14,446	$	8,720
Costs and expenses:


Total Manufacture and Supply Expenses		3,469		3,652

R&D Project expenses:
Anaphylm project expenses		1,085		2,488
AQST-108 project expenses		558		195

R&D other expenses:
Personnel costs1		2,242		2,132
Other2		319		546
Total Research and Development Expenses		4,204		5,361

Selling expenses:
Personnel costs3		1,643		694
Other4		277		2,262
Total Selling expenses		1,920		2,956

General & Administrative expenses:
Personnel costs5		5,509		4,840
Other6		3,548		11,276
Total General and Administrative Expenses		9,057		16,116

Total Selling, General and Administrative Expenses		10,977		19,072

Total costs and expenses		18,650		28,085
Loss from operations		(4,204)		(19,365)
Other income/(expenses), net		(3,853)		(3,565)
Net loss before income taxes		(8,057)		(22,930)

Net loss		$	(8,057)	$	(22,930)
Comprehensive loss		$	(8,057)	$	(22,930)

1 - R&D Personnel costs include payroll expenses, share-based compensation expenses and severance

2 - Other R&D expenses include preclinical, consulting, maintenance, and testing fees

3 - Selling Personnel costs include payroll expenses, share-based compensation expenses and severance

4 - Other Selling expenses include commercialization and other related expenses

5 - G&A Personnel costs include payroll expenses, share-based compensation expenses and severance

6 - Other General and Administrative expenses include legal/patent fees, insurance fees, IT expenses, investor relations expenses, regulatory fees, facility and other costs